Javascript must be enabled to continue!
Variety and complexity of chromosome 17 translocations in neuroblastoma
View through CrossRef
AbstractIn neuroblastoma, the most frequent genetic alteration is gain of chromosome arm 17q, which arises from unbalanced translocations. To document these genetic events more precisely, we performed an extensive study of chromosome 17 breakpoints in 27 neuroblastoma cell lines by using a combination of fluorescence in situ hybridization mapping with BAC/PAC clones and allele analysis with polymorphic markers. All cases exhibited one or more unbalanced chromosome 17 translocations, and 15 distinct breakpoint regions could be mapped. This high variability indicates that gene fusion or disruption events are extremely unlikely to account for the underlying oncogenic role of these translocations. However, breakpoints were not randomly distributed, most of them mapping to the proximal part of 17q. As a result of translocations, all cell lines but one exhibited gain of the 53.5 Mb→qter fragment, bordered proximally by the clone CTC‐462L7. The most telomeric breakpoint, flanked by the clone RP11‐443M10, defined the 70.9 Mb→qter fragment as a region of additional gain. In addition to chromosome gains, loss of heterozygosity for the short arm of chromosome 17 was observed in close to half the cases. It was either related to a chromosome 17 monosomy or to a uniparental isodisomy. Finally, in cases with a single normal chromosome 17, we show that the parental origin of the translocated chromosome 17 can be either distinct or identical to that of the normal chromosome. Similarly, multiple translocations within the same cell line can either involve the same or different chromosome 17 homologues, indicating the likely absence of parental origin bias in the generation of these alterations. © 2003 Wiley‐Liss, Inc.
Title: Variety and complexity of chromosome 17 translocations in neuroblastoma
Description:
AbstractIn neuroblastoma, the most frequent genetic alteration is gain of chromosome arm 17q, which arises from unbalanced translocations.
To document these genetic events more precisely, we performed an extensive study of chromosome 17 breakpoints in 27 neuroblastoma cell lines by using a combination of fluorescence in situ hybridization mapping with BAC/PAC clones and allele analysis with polymorphic markers.
All cases exhibited one or more unbalanced chromosome 17 translocations, and 15 distinct breakpoint regions could be mapped.
This high variability indicates that gene fusion or disruption events are extremely unlikely to account for the underlying oncogenic role of these translocations.
However, breakpoints were not randomly distributed, most of them mapping to the proximal part of 17q.
As a result of translocations, all cell lines but one exhibited gain of the 53.
5 Mb→qter fragment, bordered proximally by the clone CTC‐462L7.
The most telomeric breakpoint, flanked by the clone RP11‐443M10, defined the 70.
9 Mb→qter fragment as a region of additional gain.
In addition to chromosome gains, loss of heterozygosity for the short arm of chromosome 17 was observed in close to half the cases.
It was either related to a chromosome 17 monosomy or to a uniparental isodisomy.
Finally, in cases with a single normal chromosome 17, we show that the parental origin of the translocated chromosome 17 can be either distinct or identical to that of the normal chromosome.
Similarly, multiple translocations within the same cell line can either involve the same or different chromosome 17 homologues, indicating the likely absence of parental origin bias in the generation of these alterations.
© 2003 Wiley‐Liss, Inc.
Related Results
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Reshuffling yeast chromosomes with CRISPR/Cas9
Reshuffling yeast chromosomes with CRISPR/Cas9
ABSTRACTGenome engineering is a powerful approach to study how chromosomal architecture impacts phenotypes. However, quantifying the fitness impact of translocations independently ...
Exploration of novel therapeutic targets in neuroblastoma
Exploration of novel therapeutic targets in neuroblastoma
<p dir="ltr">Neuroblastoma is a malignancy of the sympathetic nervous system occurring in early childhood. It accounts for approximately 6% of all childhood cancers and is a ...
Exploration of novel therapeutic targets in neuroblastoma
Exploration of novel therapeutic targets in neuroblastoma
<p dir="ltr">Neuroblastoma is a malignancy of the sympathetic nervous system occurring in early childhood. It accounts for approximately 6% of all childhood cancers and is a ...
Mitigation translocation for conservation of New Zealand skinks
Mitigation translocation for conservation of New Zealand skinks
<p>Worldwide, human development is leading to the expansion and intensification of land use, with increasing encroachment on natural habitats. A rising awareness of the delet...
Overview of plant species translocations in Luxembourg
Overview of plant species translocations in Luxembourg
In Luxembourg, 34 % of native plants and archaeophytes are considered threatened or regionally extinct. Species translocations have been implemented in Luxembourg for more than 25 ...
Data from SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma
Data from SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma
<div>Abstract<p>Survival rates among patients with high-risk neuroblastoma remain low and novel therapies for recurrent neuroblastomas are required. <i>ALK</i&...
Data from SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma
Data from SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma
<div>Abstract<p>Survival rates among patients with high-risk neuroblastoma remain low and novel therapies for recurrent neuroblastomas are required. <i>ALK</i&...

